Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

Assuntina G. Sacco, Ezra E.W. Cohen, Francis P. Worden et al.|The Lancet Oncology|2021

Cited by 257